Pursuing an integrated therapeutic and companion diagnostic strategy

We are seeking to extend the lives of cancer patients by leveraging our CELsignia platform to develop therapeutics and companion diagnostics. Our therapeutic strategy utilizes CELsignia’s unique insights into tumor cell biology to identify and then develop potential first-in-class or best-in-class targeted therapies. Our companion diagnostic strategy utilizes CELsignia to support development of new indications for already approved targeted therapies.

Gedatolisib Pipeline

CELsignia Pipeline

The PI3K – mTOR Pathway

How and why we target the PI3K and mTOR pathway in cancer

Gedatolisib

Internal development of a pan-PI3K/mTOR inhibitor